RxDoctor Payments Data

Brittany Gamberi, APRN

Family · Natchez, MSNPI 1285332064

Payments from drug & device makers

$2,227in general payments, 2019–2025

Across 115 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$791
  • GSK$246
  • AstraZeneca$238
  • Astellas Pharma US Inc$215
  • Boehringer Ingelheim$165
  • Lilly USA, LLC$152
  • plus $419 from 7 others

What the payments were for

  • Food & beverage$2,16297%
  • Education$653%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,227 in reported general payments places this provider in the 80th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$130,403
Medicare patients
305
Services billed
2,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide167$219,759
JardianceEmpagliflozin116$168,110
FarxigaDapagliflozin Propanediol125$157,566
MounjaroTirzepatide114$123,648
LinzessLinaclotide111$107,674
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$69,632
TradjentaLinagliptin54$61,853
EliquisApixaban24$30,458
MyrbetriqMirabegron33$29,375
TrulicityDulaglutide21$25,723
Tresiba Flextouch U-200Insulin Degludec25$25,091
TrintellixVortioxetine Hydrobromide26$23,117
XareltoRivaroxaban16$21,739
JanuviaSitagliptin Phosphate15$21,234
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$20,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$165$229,963170 claims
Novo NordiskOzempic$67$219,759167 claims
AstraZenecaFarxiga, Symbicort$238$161,372136 claims
Lilly USA, LLCMounjaro, Trulicity$152$149,371135 claims
AbbVieLinzess, Vraylar, Synthroid$791$129,171148 claims
GSKTrelegy Ellipta$246$69,63265 claims
Astellas Pharma US IncMyrbetriq$215$29,37533 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$44$23,11726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,007 family providers in Mississippi.

Other family in Natchez

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →